Granulocyte-macrophage colony-stimulating factor to increase efficacy of mitoxantrone, etoposide and cytarabine in previously untreated elderly patients with acute myeloid leukaemia: a Swedish multicentre randomized trial
C. Löfgren, C. Paul, M. Åström, R. Hast, M. Hedenius, R. Lerner,
J. Liliemark, I. Nilsson, S. Rödjer, B. Simonsson, D. Stockelberg, U. Tidefelt, M. Björkholm,
R. Lerner
Huddinge University Hospital, Stockholm
Södersjukhuset, Stockholm
Search for more papers by this authorC. Löfgren, C. Paul, M. Åström, R. Hast, M. Hedenius, R. Lerner,
J. Liliemark, I. Nilsson, S. Rödjer, B. Simonsson, D. Stockelberg, U. Tidefelt, M. Björkholm,
R. Lerner
Huddinge University Hospital, Stockholm
Södersjukhuset, Stockholm
Search for more papers by this authorChristina Löfgren, Department of Hematology, M 54 Huddinge University Hospital, SE 141 86 Stockholm, Sweden.
E-mail: [email protected]
Summary
A total of 110 patients, aged 64 years or over, with de novo acute myeloid leukaemia (AML) and white blood cell counts <50 × 109/l were treated with 3 d of cytarabine 1 g/m2 twice daily, mitoxantrone 12 mg/m2 and etoposide 200 mg/m2, randomized with or without the addition of granulocyte-macrophage colony-stimulating factor (GM-CSF) 200 μg/m2. The primary aim was to evaluate the effect of GM-CSF on the remission rate. Secondary aims included comparison of duration of remission, survival and infectious complications and the impact of maintenance therapy with thioguanine. Complete remission (CR) was achieved by 64% of patients without GM-CSF, and by 65% of patients who received GM-CSF, the median remission duration was 13 vs. 6 months, the median overall survival (OS) was 14 vs. 9 months, the mean time to neutrophil recovery was 25 vs. 17 d (P = 0·03) and the number of positive blood cultures was 46 vs. 39 (P = 0·05) respectively. The impact of thioguanine remains unanswered since only 30 patients remained in CR after consolidation therapy. We conclude that induction therapy is feasible with acceptable toxicity in elderly patients with AML, albeit with a high relapse rate and short OS. GM-CSF prior to, and in combination with, induction treatment reduced the time to neutrophil recovery and the number of neutropenic septicaemia cases but did not improve the OS of AML in the elderly.
References
- Andersson, J.E., Kopecky, K.J., Willman, C.L., Head, D., O'Donell, M.R., Luthardt, F.W., Norwood, T.H., Chen, I.M., Balcerzak, S.P., Johnson, S.P. & Appelbaum, F.R. (2002) Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicine: a Southwest Oncology Group Study. Blood, 100, 3869–3876.
- Antman, K., Griffin, J., Elias, A., Socinski, M., Ryan, L., Cannistra, S., Oette, D., Whitley, M., Frei, E.R. & Schnipper, L. (1988) Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. New England Journal of Medicine, 319, 593–598.
- Asano, S., Shibuya, T., Okamura, S., Yamaga, S., Otsuka, T. & Niho, Y. (1987) Effect of human recombinant granulocyte/macrophage colony-stimulating factor and native granulocyte colony-stimulating factor on clonogenic leukemic blast cells. Cancer Research, 47, 5647–5648.
- Bennet, C.L., Hynes, D., Godwin, J., Stinson, T.J., Golub, R.M. & Appelbaum, F.R. (2001) Economic analysis of granulocyte colony stimulating factor as adjunct therapy for older patients with acute myelogenous leukemia (AML): estimates from a Southwest Oncology Group trial. Cancer Investigation, 19, 603–610.
- Bennett, J., Catovsky, D., Daniel, M.-T., Flandrin, G., Galton, D.A., Gralnick, H.R. & Sultan C. (1976) Proposals for the classification of acute leukemias. British Journal of Haematology, 33, 451–458.
- Bernstein, S., Brunetto, V., Davey, F., Wurster-Hill, D., Mayer, R., Stone, R., Schiffer, C. & Bloomfield, C. (1996) Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French-American-British criteria; a Cancer and Leukemia Group B Study. Journal of Clinical Oncology, 14, 2486–2494.
- Bettelheim, P., Valent, P., Andreff, M., Tafuri, A., Haimi, J., Gorischek, C., Muhm, M., Sillaber, C., Haas, O., Vieder, L., Maurer, D., Schultz, G., Spieser, W., Giessler, K., Kier, P., Hinterberger, W. & Lechner, K. (1991) Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia. Blood, 77, 700–711.
- Björkholm, M., Bjornsdottir, J., Stenke, L. & Grimfors, G. (1990) Mitoxantrone, etoposide and cytarabine in the treatment of acute nonlymphocytic leukemia. Oncology, 47, 112–114.
- Bjorkholm, M., Liliemark, J., Gahrton, G., Grimfors, G., Gruber, A., Hast, R., Juliusson, G., Jarnmark, M., Killander, A., Kimby, E., Lerner, R., Ljungman, P., Lonnquist, B., Palmblad, J., Paul, C., Petterson, C., Simonsson, B., Stalfelt, A.-M., Stenke, L., Sundstrom, C., Tidefelt, U., Uden, A.-M., Oberg, G., Ost, A. (1995) Mitoxantrone, etoposide and ara-C vs doxorubicin-DNA, ara-C, thioguanine, vincristine and prednisolone in the treatment of patients with acute myelocytic leukaemia. A randomized comparison. European Journal of Haematology, 55, 19–23.
- Estey, E., Thall, P., Beran, M., Kantarjian, H., Pierce, S. & Keating, M. (1997) Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia (AML) on outcome of AML-type chemotherapy. Blood, 90, 2969–2977.
- Estrov, Z., Estey, E., Andreeff, M., Talpaz, M., Kurzrock, R., Reading, C., Deisseroth, A. & Gutterman, J. (1992) Comparison of in vivo and in vitro effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with acute myeloid leukemia. Experimental Hematology, 20, 558–564.
- Godwin, J.E., Kopecky, K., Head, D., Willman, C., Leith, C., Hynes, H., Balcerak, S. & Appelbaum, F. (1998) A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated myeloid leukemia: a Southwest Oncology Group study (9030). Blood, 91, 3607–3615.
- Griffin, J., Young, D., Herrmann, F., Wiper, D., Wagner, K. & Sabbath, K. (1986) Effects of recombinant human GM-CSF on proliferation of clonogenic cells in acute myeloblastic leukemia. Blood, 67, 1448–1453.
- Hast, R., Hellström-Lindberg, E., Ohm, L., Björkholm, M., Celsing, F., Dahl, I., Dybedal, I., Gahrton, G., Lindberg, G., Lerner, R., Linder, O., Löfvenberg, E., Nihlsson-Ehle, H., Paul, C., Samuelsson, J., Tangen, J., Tidefelt, U., Turesson, I., Wahlin, A., Wallvik, J., Winquist, I., Öberg, G. & Bernell, P. (2003) No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative disease. Leukemia, 9, 1827–1833.
- Heil, G., Hoelzer, D., Sanz, M.A., Lechner, K., Yin, J.L., Papa, G., Noens, L., Szer, J., Ganser, A., O'Brien, C., Matcham, J. & Barge, A. (1997) A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group. Blood, 90, 4710–4718.
- Kalaycio, M., Pohlman, B., Lichtin, A., Hussein, M., Tripp, B. & Andresen, S. (2001) Chemotherapy for AML in elderly with cytarabine, mitoxantrone and granulocyte-macrophage colony-stimulating factor. American Journal of Clinical Oncology, 24, 58–63.
- Kaplan, E.L. & Meier, P. (1958) Nonparametric estimation from incomplete observations. Journal of American Statistical Association, 53, 457–481.
- Leith, C., Kopecky, K. & Goodwin, J. (1997) Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group Study. Blood, 89, 3323–3329.
- Rees, J., Gray, R., Swirsky, D. & Hayhoe, F. (1986) Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial. Lancet, 2, 1236–1241.
- Rowe, J. (1998) Treatment of acute myeloid leukemia with cytokines: effect on duration of neutropenia and response to infections. Clinical Infectious Diseases, 26, 1290–1294.
- Rowe, J., Andersen, J. & Mazza, J. (1995) Randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55–70 years of age) with acute myelogenous leukemia: a study of Eastern Cooperative Oncology Group (E1490). Blood, 332, 1671–1677.
- Shepherd, J.D., Reece, D.E. & Barnett, M.J. (1993) Induction therapy for acute myelogenous leukemia in patients over 60 years with intermediate-dose cytosine arabinoside, mitoxantrone and etoposide. Leukemia Lymphoma, 9, 211–215.
- Slovak, M., Kopecky, K. & Cassileth, P. (1998) Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood, 96, 4075–4083.
- Stone, R.M., Berg, D.T., George, S.L., Dodge, R.K., Paciucci, P.A., Schulman, P., Lee, E.J., Moore, J.O., Powell, B.L. & Schiffer, C.A. (1995) Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia cancer and leukemia group B. New England Journal of Medicine, 332, 1671–1677.
- Stone, R., Berg, D., George, S., Dodge, R., Paciucci, P., Schulman, P., Lee, E., Moore, J., Powell, B., Baer, M., Bloomfield, C. & Schiffer, C. (2001) Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood, 98, 548–553.
- Sundman-Engberg, B., Tidefelt, U. & Paul, C. (1996) Effect of cytokines on the toxicity of cytostatic drugs on leukemic cells in vitro and in vivo. European Journal of Haematology, 56, 1–6.
- Tucker, J., Thomas, S., Gregpry, W., Ganesan, T., Malik, S., Lim, J.A., Willis, L., Rohatiner, A. & Lister, T. (1990) Acute myeloid leukemia in elderly adults. Hematology Oncology, 8, 13–21.
Citing Literature
